Inclusion Criteria:

          1. Male or female patients age ≥ 18 years of age at the time of informed consent

          2. HLA-A*0201 positive, confirmed by central laboratory

          3. NY-ESO-1 and/or LAGE-1A positive tumor confirmed by the central laboratory

          4. Arm 1: Patients must be refractory to or intolerant to all existing therapies known to
             provide clinical benefit for their condition.

          5. Arm 2: Subjects will have received the following previous therapies:

               1. NSCLC — PD-1/PD-L1 inhibitor

               2. Patients with NSCLC and an EGFR or ALK genomic tumor aberration must have disease
                  progression after treatment with Health Authority-approved agents for these
                  aberrations

               3. Urothelial cancer — PD-1/PD-L1 inhibitor

               4. Synovial sarcoma — at least one prior chemotherapy regimen

          6. Arm 1 only: Histologically confirmed diagnosis of advanced NSCLC, melanoma, urothelial
             carcinoma, or synovial sarcoma

          7. Arm 2 only: Histologically confirmed diagnosis of advanced NSCLC, urothelial
             carcinoma, or synovial sarcoma

          8. Arm 2 only: Disease amenable to biopsy

          9. Arm 2 only: Measurable disease to RECIST v.1.1 criteria

        Exclusion Criteria:

        Impaired baseline organ function as evaluated by out-of-range laboratory values 2. History
        of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or
        monoclonal antibodies 3. Clinically significant cardiac disease or impaired cardiac
        function 4. Presence of symptomatic or untreated central nervous system (CNS) metastases 5.
        Active infection requiring systemic antibiotic therapy 6. Known history of human
        immunodeficiency virus infection (HIV) 7. Active hepatitis B virus (HBV) or hepatitis C
        virus (HCV) infection 8. Malignant disease, other than that being treated in this study 9.
        Patients receiving systemic steroid therapy or any other systemic immunosuppressive
        medication. Local steroid therapies are acceptable 10. Systemic anti-cancer therapy within
        2 weeks of the first dose of study drug.

        11. Major surgery within 2 weeks of the first dose of study drug 12. Radiotherapy within 2
        weeks of the first dose of study drug, with the exception of palliative radiotherapy to a
        limited field 13. Use of hematopoietic colony-stimulating growth factors (eg, G-CSF,
        GM-CSF, M-CSF) ≤ 2 weeks prior to start of study drug 14. Pregnant, likely to become
        pregnant, or lactating women